title: Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology.
abstract: Propylisopropylacetic acid (PIA) is a constitutional isomer of valproic acid (VPA). It has previously been found to be a weak antiepileptic, but in common with mood stabilizers, causes inositol depletion and growth cone spreading, suggesting the basis of a new series of mood stabilizers. To assess this possibility, we have compared the effects of racemic (R,S)-PIA and its individual enantiomers to those of the mood stabilizers lithium (Li+), VPA and carbamazepine (CBZ). Unlike Li+ and VPA, but in common with CBZ and (R,S)-PIA, neither (R)-PIA nor (S)-PIA enantiomer induces T-cell factor (TCF)-mediated gene expression. However, as seen for other mood stabilizers, both enantiomers are potent inducers of growth cone spreading. To investigate the mechanism for these effects, we examined changes in the actin cytoskeleton following drug treatment with Li+, VPA, CBZ, (R,S)-PIA or its individual enantiomers. All exhibit a redistribution of F-actin to the growth cone periphery, a feature of spread growth cones. (R,S)-PIA has the strongest effect as it also elevates F-actin polymerization at the cell periphery. This change in the actin cytoskeleton is associated with a substantial increase in F-actin-rich protrusions on the surface of the growth cone and in its close vicinity. These results demonstrate an effect of (R,S)-PIA on the neuronal actin cytoskeleton shared in common with other mood stabilizers, and suggest a potential to induce structural changes within the CNS.
authors.affiliation: Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
authors.forename: Jakob A
authors.initials: JA
authors.lastname: Shimshoni
authors.forename: Emma C
authors.initials: EC
authors.lastname: Dalton
authors.forename: Peter
authors.initials: P
authors.lastname: Watson
authors.forename: Yagen
authors.initials: Y
authors.lastname: Boris
authors.forename: Meir
authors.initials: M
authors.lastname: Bialer
authors.forename: Adrian J
authors.initials: AJ
authors.lastname: Harwood
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D018692:Antimanic Agents / Q000494:pharmacology; D002220:Carbamazepine / Q000494:pharmacology; D003599:Cytoskeleton / Q000187:drug effects; D005727:Ganglia, Spinal / Q000166:cytology / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects; D020439:Growth Cones / Q000187:drug effects* / Q000648:ultrastructure*; D007150:Immunohistochemistry; D018021:Lithium Chloride / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects* / Q000648:ultrastructure*; D009924:Organ Culture Techniques; D051381:Rats; D017207:Rats, Sprague-Dawley; D013237:Stereoisomerism; D013601:T-Lymphocytes / Q000502:physiology; D014635:Valproic Acid / Q000494:pharmacology*
chemical_list: D000199:Actins; D018692:Antimanic Agents; D002220:Carbamazepine; D014635:Valproic Acid; D018021:Lithium Chloride
references.citation: FEBS Lett. 1995 Mar 13;361(1):1-7
references.pmid: 7890024
references.citation: Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9
references.pmid: 8710892
references.citation: Biochem Biophys Res Commun. 2001 Jan 26;280(3):720-5
references.pmid: 11162580
references.citation: Biochem Pharmacol. 2003 Jul 15;66(2):179-89
references.pmid: 12826261
references.citation: Prog Neurobiol. 2008 Nov;86(3):281-96
references.pmid: 18786602
references.citation: Trends Neurosci. 2007 Apr;30(4):142-9
references.pmid: 17324475
references.citation: J Biol Chem. 2001 Sep 28;276(39):36734-41
references.pmid: 11473107
references.citation: CNS Neurol Disord Drug Targets. 2007 Jun;6(3):193-204
references.pmid: 17511616
references.citation: J Cell Sci. 1998 May;111 ( Pt 10):1351-61
references.pmid: 9570753
references.citation: Neurosci Lett. 2001 Oct 26;312(3):141-4
references.pmid: 11602330
references.citation: Mol Cell Neurosci. 2003 Aug;23(4):626-37
references.pmid: 12932442
references.citation: Biochem Soc Trans. 2004 Nov;32(Pt 5):799-802
references.pmid: 15494019
references.citation: J Neurosci. 2004 Jul 28;24(30):6791-8
references.pmid: 15282284
references.citation: Mol Pharmacol. 2007 Mar;71(3):884-92
references.pmid: 17167030
references.citation: J Biol Chem. 1980 Nov 25;255(22):10896-901
references.pmid: 6253491
references.citation: J Med Chem. 2007 Dec 13;50(25):6419-27
references.pmid: 17994680
references.citation: Curr Opin Psychiatry. 2007 Jan;20(1):1-7
references.pmid: 17143074
references.citation: Eur J Immunol. 1986 Jul;16(7):859-61
references.pmid: 3013648
references.citation: Mol Pharmacol. 2005 May;67(5):1426-33
references.pmid: 15687223
references.citation: Bipolar Disord. 2005 Jun;7(3):260-5
references.pmid: 15898963
references.citation: Cell. 1989 Nov 3;59(3):411-9
references.pmid: 2553271
references.citation: J Neurochem. 1999 Mar;72(3):1327-30
references.pmid: 10037507
references.citation: Biol Psychiatry. 2004 Apr 15;55(8):781-4
references.pmid: 15050857
references.citation: Braz J Psychiatry. 2004 Sep;26(3):180-8
references.pmid: 15645064
references.citation: J Cell Sci. 1999 Oct;112 ( Pt 19):3373-84
references.pmid: 10504342
references.citation: Annu Rev Cell Dev Biol. 2002;18:601-35
references.pmid: 12142283
references.citation: Biol Psychiatry. 2005 Jul 15;58(2):151-7
references.pmid: 15922309
references.citation: Methods Enzymol. 1979;58:94-109
references.pmid: 423795
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):209-24
references.pmid: 14751416
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5099-104
references.pmid: 15044694
references.citation: Mol Cell Neurosci. 2002 Jun;20(2):257-70
references.pmid: 12093158
references.citation: Biol Psychiatry. 1999 Apr 15;45(8):995-1003
references.pmid: 10386182
references.citation: Behav Pharmacol. 2007 Sep;18(5-6):419-30
references.pmid: 17762510
references.citation: Neuron. 2003 Oct 9;40(2):209-27
references.pmid: 14556705
references.citation: Nature. 2002 May 16;417(6886):292-5
references.pmid: 12015604
references.citation: Science. 1997 Mar 21;275(5307):1784-7
references.pmid: 9065401
references.citation: Hum Psychopharmacol. 2002 Oct;17(7):321-7
references.pmid: 12415549
references.citation: Int J Neuropsychopharmacol. 2004 Dec;7(4):387-90
references.pmid: 15315719
references.citation: Annu Rev Neurosci. 2005;28:251-74
references.pmid: 16022596
references.citation: Biol Psychiatry. 2004 Dec 1;56(11):868-74
references.pmid: 15576064